GSK’s (GSK) “Hold” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “hold” rating restated by research analysts at Deutsche Bank Aktiengesellschaft in a report issued on Wednesday,Digital Look reports. They currently have a GBX 1,900 price objective on the stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential downside of 1.70% from the stock’s current price.

GSK has been the topic of several other research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a report on Tuesday, April 14th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 target price on shares of GSK in a report on Thursday, March 26th. Citigroup reduced their target price on shares of GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Shore Capital Group reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, GSK has a consensus rating of “Hold” and a consensus target price of GBX 2,034.29.

GSK Stock Performance

GSK stock opened at GBX 1,932.91 on Wednesday. The firm’s fifty day moving average price is GBX 2,006.72 and its 200-day moving average price is GBX 1,949.60. The company has a debt-to-equity ratio of 106.74, a quick ratio of 0.73 and a current ratio of 0.79. The stock has a market cap of £77.16 billion, a P/E ratio of 13.60, a price-to-earnings-growth ratio of 1.24 and a beta of 0.30. GSK has a fifty-two week low of GBX 1,288.61 and a fifty-two week high of GBX 2,282.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The firm had revenue of GBX 762.90 billion for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. On average, equities research analysts expect that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Jonathan Symonds bought 5,000 shares of the business’s stock in a transaction dated Friday, March 20th. The shares were purchased at an average price of GBX 1,951 per share, with a total value of £97,550. Also, insider Anne Beal bought 196 shares of the business’s stock in a transaction dated Friday, March 20th. The shares were bought at an average cost of GBX 5,179 per share, for a total transaction of £10,150.84. In the last 90 days, insiders have purchased 9,619 shares of company stock valued at $19,452,794. Corporate insiders own 0.20% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.